New signalling pathway involved in the anti-proliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase

Francesca Bini, Alessia Frati, Mercedes Garcia-Gil, Chiara Battistini, Maria Granado, Maria Martinesi, Marco Mainardi, Eleonora Vannini, Federico Luzzati, Matteo Caleo, Paolo Peretto, Antonio Gomez-Muñoz, Elisabetta Meacci

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), a crucial regulator of calcium/phosphorus homeostasis, has important physiological effects on growth and differentiation in a variety of malignant and non-malignant cells. Synthetic structural hormone analogues, with lower hypercalcemic side effects, are currently under clinical investigation. Sphingolipids appear to be crucial bioactive factors in the control of the cell fate: the phosphorylated forms, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P), are mitogenic factors, whereas sphingosine and ceramide (Cer) usually act as pro-apoptotic agents. Although many studies correlate S1P function to impaired cell growth, the relevance of C1P/Cer system and its involvement in neuroblastoma cells remain to be clarified. Here, we demonstrated the anti-proliferative effect of 1,25(OH)2D3 as well as of its structural analogues, ZK156979 and ZK191784, in human SH-SY5Y cells, as judged by [3H]thymidine incorporation, cell growth and evaluation of active ERK1/2 levels. The inhibition of ceramide kinase (CerK), the enzyme responsible for C1P synthesis, by specific gene silencing or pharmacological inhibition, drastically reduced cell proliferation. 1,25(OH)2D3 and ZK191784 treatment induced a significant decrease in CerK expression and C1P content, and an increase of Cer. Notably, the treatment of SH-SY5Y cells with ZK159222, antagonist of 1,25(OH) 2D3 receptor, trichostatin A, inhibitor of histone deacetylases, and COUP-TFI-siRNA prevented the decrease of CerK expression elicited by 1,25(OH)2D3 supporting the involvement of VDR/COUP-TFI/histone deacetylase complex in CerK regulation. Altogether, these findings provide the first evidence that CerK/C1P axis acts as molecular effector of the anti-proliferative action of 1,25(OH)2D3 and its analogues, thereby representing a new possible target for anti-cancer therapy of human neuroblastoma.

Original languageEnglish
Pages (from-to)524-537
Number of pages14
JournalNeuropharmacology
Volume63
Issue number4
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Cholecalciferol
Neuroblastoma
Ceramides
Histone Deacetylases
trichostatin A
Growth
Sphingolipids
Sphingosine
Calcitriol
Gene Silencing
ceramide kinase
Thymidine
Phosphorus
Small Interfering RNA
Homeostasis
Cell Proliferation
ceramide 1-phosphate
Hormones
Pharmacology
Calcium

Keywords

  • Cell growth
  • Ceramide 1-phosphate
  • SH-SY5Y cells
  • Sphingolipids
  • VDR

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

New signalling pathway involved in the anti-proliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase. / Bini, Francesca; Frati, Alessia; Garcia-Gil, Mercedes; Battistini, Chiara; Granado, Maria; Martinesi, Maria; Mainardi, Marco; Vannini, Eleonora; Luzzati, Federico; Caleo, Matteo; Peretto, Paolo; Gomez-Muñoz, Antonio; Meacci, Elisabetta.

In: Neuropharmacology, Vol. 63, No. 4, 09.2012, p. 524-537.

Research output: Contribution to journalArticle

Bini, F, Frati, A, Garcia-Gil, M, Battistini, C, Granado, M, Martinesi, M, Mainardi, M, Vannini, E, Luzzati, F, Caleo, M, Peretto, P, Gomez-Muñoz, A & Meacci, E 2012, 'New signalling pathway involved in the anti-proliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase', Neuropharmacology, vol. 63, no. 4, pp. 524-537. https://doi.org/10.1016/j.neuropharm.2012.04.026
Bini, Francesca ; Frati, Alessia ; Garcia-Gil, Mercedes ; Battistini, Chiara ; Granado, Maria ; Martinesi, Maria ; Mainardi, Marco ; Vannini, Eleonora ; Luzzati, Federico ; Caleo, Matteo ; Peretto, Paolo ; Gomez-Muñoz, Antonio ; Meacci, Elisabetta. / New signalling pathway involved in the anti-proliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase. In: Neuropharmacology. 2012 ; Vol. 63, No. 4. pp. 524-537.
@article{3267bbb821944f78be999fa93078a90c,
title = "New signalling pathway involved in the anti-proliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase",
abstract = "1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), a crucial regulator of calcium/phosphorus homeostasis, has important physiological effects on growth and differentiation in a variety of malignant and non-malignant cells. Synthetic structural hormone analogues, with lower hypercalcemic side effects, are currently under clinical investigation. Sphingolipids appear to be crucial bioactive factors in the control of the cell fate: the phosphorylated forms, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P), are mitogenic factors, whereas sphingosine and ceramide (Cer) usually act as pro-apoptotic agents. Although many studies correlate S1P function to impaired cell growth, the relevance of C1P/Cer system and its involvement in neuroblastoma cells remain to be clarified. Here, we demonstrated the anti-proliferative effect of 1,25(OH)2D3 as well as of its structural analogues, ZK156979 and ZK191784, in human SH-SY5Y cells, as judged by [3H]thymidine incorporation, cell growth and evaluation of active ERK1/2 levels. The inhibition of ceramide kinase (CerK), the enzyme responsible for C1P synthesis, by specific gene silencing or pharmacological inhibition, drastically reduced cell proliferation. 1,25(OH)2D3 and ZK191784 treatment induced a significant decrease in CerK expression and C1P content, and an increase of Cer. Notably, the treatment of SH-SY5Y cells with ZK159222, antagonist of 1,25(OH) 2D3 receptor, trichostatin A, inhibitor of histone deacetylases, and COUP-TFI-siRNA prevented the decrease of CerK expression elicited by 1,25(OH)2D3 supporting the involvement of VDR/COUP-TFI/histone deacetylase complex in CerK regulation. Altogether, these findings provide the first evidence that CerK/C1P axis acts as molecular effector of the anti-proliferative action of 1,25(OH)2D3 and its analogues, thereby representing a new possible target for anti-cancer therapy of human neuroblastoma.",
keywords = "Cell growth, Ceramide 1-phosphate, SH-SY5Y cells, Sphingolipids, VDR",
author = "Francesca Bini and Alessia Frati and Mercedes Garcia-Gil and Chiara Battistini and Maria Granado and Maria Martinesi and Marco Mainardi and Eleonora Vannini and Federico Luzzati and Matteo Caleo and Paolo Peretto and Antonio Gomez-Mu{\~n}oz and Elisabetta Meacci",
year = "2012",
month = "9",
doi = "10.1016/j.neuropharm.2012.04.026",
language = "English",
volume = "63",
pages = "524--537",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - New signalling pathway involved in the anti-proliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase

AU - Bini, Francesca

AU - Frati, Alessia

AU - Garcia-Gil, Mercedes

AU - Battistini, Chiara

AU - Granado, Maria

AU - Martinesi, Maria

AU - Mainardi, Marco

AU - Vannini, Eleonora

AU - Luzzati, Federico

AU - Caleo, Matteo

AU - Peretto, Paolo

AU - Gomez-Muñoz, Antonio

AU - Meacci, Elisabetta

PY - 2012/9

Y1 - 2012/9

N2 - 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), a crucial regulator of calcium/phosphorus homeostasis, has important physiological effects on growth and differentiation in a variety of malignant and non-malignant cells. Synthetic structural hormone analogues, with lower hypercalcemic side effects, are currently under clinical investigation. Sphingolipids appear to be crucial bioactive factors in the control of the cell fate: the phosphorylated forms, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P), are mitogenic factors, whereas sphingosine and ceramide (Cer) usually act as pro-apoptotic agents. Although many studies correlate S1P function to impaired cell growth, the relevance of C1P/Cer system and its involvement in neuroblastoma cells remain to be clarified. Here, we demonstrated the anti-proliferative effect of 1,25(OH)2D3 as well as of its structural analogues, ZK156979 and ZK191784, in human SH-SY5Y cells, as judged by [3H]thymidine incorporation, cell growth and evaluation of active ERK1/2 levels. The inhibition of ceramide kinase (CerK), the enzyme responsible for C1P synthesis, by specific gene silencing or pharmacological inhibition, drastically reduced cell proliferation. 1,25(OH)2D3 and ZK191784 treatment induced a significant decrease in CerK expression and C1P content, and an increase of Cer. Notably, the treatment of SH-SY5Y cells with ZK159222, antagonist of 1,25(OH) 2D3 receptor, trichostatin A, inhibitor of histone deacetylases, and COUP-TFI-siRNA prevented the decrease of CerK expression elicited by 1,25(OH)2D3 supporting the involvement of VDR/COUP-TFI/histone deacetylase complex in CerK regulation. Altogether, these findings provide the first evidence that CerK/C1P axis acts as molecular effector of the anti-proliferative action of 1,25(OH)2D3 and its analogues, thereby representing a new possible target for anti-cancer therapy of human neuroblastoma.

AB - 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), a crucial regulator of calcium/phosphorus homeostasis, has important physiological effects on growth and differentiation in a variety of malignant and non-malignant cells. Synthetic structural hormone analogues, with lower hypercalcemic side effects, are currently under clinical investigation. Sphingolipids appear to be crucial bioactive factors in the control of the cell fate: the phosphorylated forms, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P), are mitogenic factors, whereas sphingosine and ceramide (Cer) usually act as pro-apoptotic agents. Although many studies correlate S1P function to impaired cell growth, the relevance of C1P/Cer system and its involvement in neuroblastoma cells remain to be clarified. Here, we demonstrated the anti-proliferative effect of 1,25(OH)2D3 as well as of its structural analogues, ZK156979 and ZK191784, in human SH-SY5Y cells, as judged by [3H]thymidine incorporation, cell growth and evaluation of active ERK1/2 levels. The inhibition of ceramide kinase (CerK), the enzyme responsible for C1P synthesis, by specific gene silencing or pharmacological inhibition, drastically reduced cell proliferation. 1,25(OH)2D3 and ZK191784 treatment induced a significant decrease in CerK expression and C1P content, and an increase of Cer. Notably, the treatment of SH-SY5Y cells with ZK159222, antagonist of 1,25(OH) 2D3 receptor, trichostatin A, inhibitor of histone deacetylases, and COUP-TFI-siRNA prevented the decrease of CerK expression elicited by 1,25(OH)2D3 supporting the involvement of VDR/COUP-TFI/histone deacetylase complex in CerK regulation. Altogether, these findings provide the first evidence that CerK/C1P axis acts as molecular effector of the anti-proliferative action of 1,25(OH)2D3 and its analogues, thereby representing a new possible target for anti-cancer therapy of human neuroblastoma.

KW - Cell growth

KW - Ceramide 1-phosphate

KW - SH-SY5Y cells

KW - Sphingolipids

KW - VDR

UR - http://www.scopus.com/inward/record.url?scp=84863620876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863620876&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2012.04.026

DO - 10.1016/j.neuropharm.2012.04.026

M3 - Article

C2 - 22579669

AN - SCOPUS:84863620876

VL - 63

SP - 524

EP - 537

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 4

ER -